At a glance
- Originator Eisai Co Ltd
- Class Anti-inflammatories
- Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 31 May 1999 New profile
- 31 May 1999 Preclinical development for Inflammation in Japan (PO)